EMA Initiates DARWIN EU Coordination Centre
EMA has started the establishment of its Data Analysis and Real World Interrogation Network (DARWIN EU) Coordination Centre.
The European Medicines Agency (EMA) has revealed that it has started the establishment of its Data Analysis and Real World Interrogation Network (DARWIN EU) Coordination Centre, in a Feb. 9, 2022 press release.
The DARWIN EU Coordination Centre is aimed at the development and management of real-world healthcare data sources across the European Union (EU). Additionally, the center will be used to conduct scientific studies that are requested by medicines regulators and, later on, those that have been requested by other stakeholders.
It is hoped that the center will provide EMA and other national competent authorities in the region with access to valid and trustworthy real-world evidence. Many stakeholders are expected to benefit through this resource, which will support decision-making on the development, authorization, and surveillance of medicines. Furthermore, EMA expects that the center will be an invaluable resource for the preparation and response to future healthcare crises and pandemics.
The Erasmus University Medical Center Rotterdam will be working with EMA as a contractor on the establishment of the DARWIN EU Coordination Centre. More information is available on EMA’s website.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
